Patent ID: 8143251
Filing Date: 2012-03-27
Classification: A61P,C07D

Abstract:
1. A method of treating bladder cancer, cervical cancer, cholangiocarcinoma cancer, colorectal cancer, esophageal cancer, head and neck cancer, liver cancer, nasopharyngeal cancer, thyroid cancer, osteosarcoma, synovial sarcoma, MFH/fibrosarcoma, leiomyosarcoma, Kaposi's sarcoma, multiple myeloma, lymphoma, adult T cell leukemia, acute myelogenous leukemia, chronic myeloid leukemia, astrocytoma, or Wilm's tumor in a patient, wherein said cancer is associated with dysregulation of the HGF/c-Met kinase signaling pathway, comprising administering to said patient a therapeutically effective amount of a compound of Formula I: or pharmaceutically acceptable salt thereof, wherein: Cy Cy A is H, halo, C R Q is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C W and W′ are independently absent or independently selected from C X and X′ are independently absent or independently selected from C Y and Y′ are independently absent or independently selected from C Z and Z′ are independently selected from H, halo, C wherein two adjacent —W—X—Y—Z, together with the atoms to which they are attached, optionally form a fused 4-, 5-, 6-, or 7-membered cycloalkyl ring or a fused 4-, 5-, 6-, or 7-membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, C wherein two adjacent —W′—X′—Y′—Z′, together with the atoms to which they are attached, optionally form a fused 4-, 5-, 6-, or 7-membered cycloalkyl ring or a fused 4-, 5-, 6-, or 7-membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, C R R R or R R R R or R R or R R or R R R R R R